Blomqvist C.
Malignant hypercalcaemia – a hospital survey // Acta Med. Scand.
1986. — V. 220. — P. 455 463.
Blomqvist C., Risteli L., Risteli J., Virkkunen P., Sarna S., Elomaa I.
Markers of type
I collagen degradation and synthesis in the monitoring of treatment response in bone
metastases from breast carcinoma // Br. J. Cancer 1996 — V. 73(9). — P. 1074 1079.
Blijlevens N.M., Oosterhuis W.P., Oosten H.R., Mulder N.H.
Clinical value of TPS,
CEA and CA 15 3 in breast cancer patients // Anticancer Res. — 1995. — V. 15(6B). —
P. 2711 2716.
Blitzer P.H.
Reanalysis of the RTOG study of the palliation of symptomatic osseous
metastases // Cancer. — 1985. — V. 55. — P.1468 1472.
Blum J.L., Jones S.E., Buzdar A.U.,
è ñîàâò. A multicenter phase II study of
capecitabine in paclitaxel refractory metastatic breast cancer // J. Clin. Oncol. — 1999. —
V.17. — P. 485 493.
Boccardo F., Rubagotti A., Perrotta A.,
è ñîàâò. Ovarian ablation versus goserelin
with or without tamoxifen in pre perimenopausal patients with advanced breast cancer:
results of a multicentric Italian study // Ann. Oncol. — 1994. — V. 5. — P. 337 342.
Body J.J., Dumon J.C., Gilbert F., Nejai S., Fernandez G.
Increased production of
TNF alpha in tumor associated hypercalcaemia // J. Bone Miner. Res. — 1989. — V. 4
(Suppl.). — P. 253.
Body J.J.
Metastatic bone disease: clinical and therapeutic aspects // Bone. — 1992. —
V. 13. — P. 57 62.
Body J.J., Delmas P.D.
Urinary pyridinum cross links as markers of bone resorption
in tumor associated hypercalcaemia // J. Clin. Endocrinol. Metab. — 1992. — V. 74. —
P. 471 475.
Body J.J.
Bone metastases and tumor induced hypercalcemia // Curr. Opin. Oncol. —
1992. — V. 4. — P. 624 631.
Body J.J., Dumon J.C.
Treatment of tumor induced hypercalcaemia with the bis
phosphonate pamidronate: Dose response relationship and influence of the tumor type //
Ann. Oncol. — 1994. — V. 5. — P. 359 363.
Body J.J., Dumon J.C., Piccart M., Ford J.
Intravenous pamidronate in patients with
tumor induced osteolysis: a biochemical dose response study // J. Bone Miner. Res.
1995. — V. 10(8). — P. 1191 1196.
Body J.J.
Clinical trials in metastatic breast cancer to bone: past—present—future //
Can. J. Oncol. — 1995. — V. 5 (Suppl. 1). — P. — 16 27.
Body J.J., Coleman R.E., Piccart M.
Use of bisphosphonates in cancer patients //
Cancer Treat. Rev. — 1996. — V. 22 — P. 265 287.
Body J.J., Dumon J.C., Gineyts E., Delmas P.D.
Comparative evaluation of markers
of bone resorption in patients with breast cancer induced osteolysis before and after bis
phosphonate therapy // Br. J. Cancer 1997. — V. 75(3). — P. 408 412.
Body J.J., Bartl R., Burckhardt P., Delmas P.D., Diel I.J., Fleisch H., Kanis J.A., Kyle
R.A., Mundy G.R., Paterson A.H., Rubens R.D.
Current use of bisphosphonates in oncolo
gy. International Bone and Cancer Study Group // J. Clin. Oncol. — 1998. — V. 16(12). —
P. 3890 3899.
Bolla M., Doidj H., Lachet
è ñîàâò. Lantigene carcinoembrionnaire dans les tumers
du sein evoluation initiele et surveillance // Bull. Ñancer. — 1983. — V. 79. — ¹ 4. —
P.300 302.
217
Êîñòíûå ìåòàñòàçû ðàêà ìîëî÷íîé æåëåçû
